Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.
Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.
Gastrointest Endosc Clin N Am. 2021 Jan;31(1):27-41. doi: 10.1016/j.giec.2020.08.002. Epub 2020 Oct 21.
Barrett's esophagus (BE) is the only known precursor to esophageal adenocarcinoma (EAC), a cancer with increasing incidence and poor survival. Risk of EAC in patients with BE is higher compared with the general population. Endoscopic screening for BE is performed to identify patients earlier in the metaplasia-dysplasia-carcinoma sequence from BE to EAC to enable eradication therapy. BE screening should be considered in individuals with multiple risk factors for BE and EAC. Challenges to BE screening include the absence of a cost-effective, widely applicable minimally invasive screening tool, gastroesophageal reflux disease centric screening recommendations, and limitations of current endoscopic surveillance practice.
巴雷特食管（BE）是唯一已知的食管腺癌（EAC）前体，EAC发病率不断上升，且预后不良。与一般人群相比，BE 患者发生 EAC 的风险更高。对 BE 患者进行内镜筛查，是为了在 BE 到 EAC 的化生-异型增生-癌序列中更早地识别患者，从而能够进行根除治疗。对于具有 BE 和 EAC 多种危险因素的个体，应考虑进行 BE 筛查。BE 筛查所面临的挑战包括缺乏经济有效的、广泛适用的微创筛查工具、以胃食管反流病为中心的筛查建议，以及目前内镜监测实践的局限性。
